Key Highlights
CoSara Diagnostics Pvt. Ltd., the joint venture between Co-Dx and Ambalal Sarabhai Enterprises Limited (ASE Group), has entered into an agreement to expand its commercial footprint across South Asia. This expansion encompasses four new markets: Bangladesh, Pakistan, Nepal, and Sri Lanka.
This strategic move is projected to increase CoSara's potential market size in the region to approximately $13 billion, based on internal research and external market intelligence.
The expansion aims to promote two primary offerings: the CoSara PCR Pro® point-of-care diagnostic system and the comprehensive SARAGENE® testing portfolio. Commercialization in each market is contingent upon obtaining the necessary regulatory approvals.
CoSara has initiated the establishment of its distribution infrastructure in these four new markets. This process involves adhering to regulatory requirements, identifying target customer segments, and forging partnerships with local distribution networks.
Executive Views on Regional Expansion
Mohal Sarabhai, CEO of CoSara, emphasized the significant and growing demand for accessible, non-invasive molecular diagnostic solutions in the South Asian region. He highlighted key application areas such as tuberculosis screening, HPV testing, and respiratory infection testing.
Dwight Egan, CEO of Co-Diagnostics, views the agreement as an extension of the company's infrastructure-oriented strategy. The company is prioritizing the development of regional manufacturing capabilities and distribution networks to support product launches, a blueprint being executed across the United States, South Asia, and the Middle East and North Africa (MENA) region.
Egan noted that this approach is designed to enable Co-Dx's global expansion of its point-of-care PCR diagnostic technology platform.
To facilitate distributor recruitment, CoSara has scheduled a virtual training session for Q2 2026. A comprehensive in-person distributor meeting and training program is planned for late summer.
Current Stock Performance
Prior to Friday's surge, CODX's stock had been trading near its 52-week low of $2.04. A pre-market increase of 9.43% pushed the stock price to $2.90.
Investors should note that the PCR Pro® system and its associated platform products are still under FDA review and have not yet received authorization for commercial distribution.
In March, Co-Diagnostics also secured patent protection in Japan for its PCR platform innovations. This followed the company's successful reinstatement to NASDAQ listing compliance, ending a brief period of uncertainty regarding its qualification status.
The projected $13 billion potential market size is derived from the company's analysis and independent market research. Actual revenue realization will depend on the timeline for regulatory approvals and the pace of market adoption.